Zobrazeno 1 - 10
of 27
pro vyhledávání: '"D. Yu. Platonov"'
Autor:
V. A. Markov, D. V. Duplyakov, S. L. Konstantinov, G. V. Klein, S. B. Aksentiev, D. Yu. Platonov, E. V. Vyshlov, Е. A. Ponomarev, R. M. Rabinovich, E. L. Makarov, E. V. Kulibaba, D. S. Yunevich, O. V. Kritskaya, E. A. Baranov, O. B. Talibov, V. A. Kutsenko, A. A. Orlovsky, N. L. Vyazova, A. G. Koledinsky, A. M. Semenov, M. P. Semenov, E. B. Yarovaya, T. M. Uskach, R. M. Shakhnovich, S. N. Tereshchenko, S. S. Markin
Publikováno v:
Российский кардиологический журнал, Vol 27, Iss 8 (2022)
Aim. To study the effectiveness of Fortelyzin® in subgroups with different body weights in patients with ST-segment elevation acute myocardial infarction (STEMI) in the FRIDOM1 study and real clinical practice.Material and methods. Fortelyzin® was
Externí odkaz:
https://doaj.org/article/fb792bc541fa43af90e49ac22b725253
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 18, Iss 6, Pp 116-120 (2019)
The clinical case of the successful use of the myocardial cytoprotector trimetazidine as a universal anti-ischemic agent in a patient with hemodynamic angina due to myocardial bridging is described. The pathogenetic rationale for this prescription is
Externí odkaz:
https://doaj.org/article/8544dbd9cbf5426298ee20f5f4c0f666
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 15, Iss 2, Pp 251-257 (2019)
A recently published article [1 ] on the problems of anticoagulant therapy in patients with frailty syndrome contains two statements which highlight ri-varoxaban among other non-vitamin K antagonist oral anticoagulants (NOAC): 1) none of the randomiz
Externí odkaz:
https://doaj.org/article/3d624e6ef12e42a7854bad4b905b46e3
Autor:
V. A. Markov, D. V. Duplyakov, S. L. Konstantinov, G. V. Klein, S. B. Aksentev, D. Yu. Platonov, E. V. Vyshlov, E. A. Ponomarev, R. M. Rabinovich, E. L. Makarov, E. V. Kulibaba, D. S. Yunevich, O. V. Kritskaia, E. A. Baranov, O. B. Talibov, E. A. Gerasimets
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 11, Pp 110-116 (2018)
Aim. Evaluate the oneyear results and clinical outcomes of a multicenter randomized clinical trial FRIDOM1.Material and methods. The study FRIDOM1 was conducted in 11 clinical centers of the Russian Federation in the period 20142016. The study
Externí odkaz:
https://doaj.org/article/d356e98be2464985907eb248a4d50606
Autor:
A. V. Kontsevaya, K. Bates, E. A. Goryachkin, N. Bobrova, L. I. Syromiatnikova, Yu. V. Popova, D. Yu. Platonov, I. V. Osipova, A. M. Nedbaikin, T. N. Malorodova, O. A. Mirolyubova, D. V. Kryuchkov, L. A. Khaisheva, A. S. Galyavich, M. V. Franz, A. Yu. Efanov, D. V. Duplyakov, O. M. Drapkina, D. Leon, M. McKee
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 14, Iss 4, Pp 474-487 (2018)
Aim. To describe the characteristics of the patient with MI who is admitted to a hospital and to characterize the main diagnostic and treatment interventions in clinic.Material and methods. This study is observational and the part of big internationa
Externí odkaz:
https://doaj.org/article/59cd73494e42495eb0eb9c5e05987896
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 13, Iss 5, Pp 716-724 (2017)
The opinion is expressed in some domestic publications that rivaroxaban has the most favorable profile of drug interaction in comparison with other new oral anticoagulants (NOAC). The basis for such judgments is the summary table of drug interaction
Externí odkaz:
https://doaj.org/article/97c1a902da54498bb2b28315ac6c87ce
Autor:
E. S. Mazur, R. M. Rabinovich, V. V. Mazur, N. S. Kuznetsova, E. A. Kudryashova, S. V. Veselov, V. V. Bobkov, D. Yu. Platonov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 13, Iss 4, Pp 463-468 (2017)
Aim. To compare the efficacy and safety of thrombolytic therapy with recombinant non-immunogenic staphylokinase and tenecteplase in ST elevation myocardial infarction (STEMI) in real clinical practice.Material and methods. 84 patients with onset of S
Externí odkaz:
https://doaj.org/article/eb0fcba2b40445269d2a719439929357
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 7, Iss 6, Pp 718-724 (2016)
Aim. To analyze potential determinants of preventive behavior (PB) in patients with essential hypertension (HT) and chronic ischemic heart disease (CIHD), and to establish their significance and hierarchy. Material and methods. Patients with HT (n=28
Externí odkaz:
https://doaj.org/article/03f54dfa125f4b528206b40ac16c9778
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 8, Iss 1, Pp 51-56 (2015)
Aim. To compare vasomotor endothelial function, aortic elastic properties and characteristics of left ventricular (LV) remodeling in patients with isolated systolic (ISHT) and sistolo-diastolic (SDHT) hypertension. Material and methods. Echocardiogra
Externí odkaz:
https://doaj.org/article/5a820243b1ee45b1a006e69164f8407e
Autor:
O. V. Tsygankova, Z. G. Bondareva, Yu. I. Ragino, K. Yu. Nikolaev, D. Yu. Platonov, V. N. Maksimov, M. G. Pustovetova
Publikováno v:
Атеросклероз, Vol 11, Iss 3, Pp 42-50 (2015)
Objective: To evaluate the serum concentrations of the three markers of lysosomal hydrolases (cathepsin D, acid phosphatase (AP) and acid DNAse (aDNAase) in men with coronary heart disease (CHD), depending on the levels of testosterone (T), estradiol
Externí odkaz:
https://doaj.org/article/cd3ed468e3ff4d4ca32ac0037fc70805